Idelalisib Tablet shortage
Idelalisib Tablet is currently listed in shortage by the FDA. The FDA lists 2 affected products. This page was last refreshed from FDA data on Sep 19, 2026.
Gilead Sciences is stopping production of Zydelig (idelalisib) tablets, and this change may be permanent. No other manufacturers make this medicine, so neither the 100 mg nor 150 mg strength has a listed available source right now.
Don’t stop or change your therapy on your own — talk with your prescriber about the plan that fits you, and ask your pharmacist what’s actually available.
Do you take this drug? See the ‘What to do’ recommendation from Dr. Brian Staiger, PharmD →What’s in shortage — at a glance
These figures count only the manufacturers that reported this shortage to the FDA — not every company that makes Idelalisib Tablet. Other makers that haven’t reported a problem are shown in the green card below.
Shortage timeline
-
Apr 7, 2026Currently in shortage2 of 2 products affected.
-
Apr 7, 2026First reported to the FDA2 products first listed.
Built from FDA posting and update dates. The end date FDA publishes is the posting/update date, not a true resolution date, so durations are approximate.
What exactly is on backorder — by manufacturer
Manufacturer: Gilead Sciences, Inc. 📞 800-445-3235 2 NDCS click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| To Be Discontinued | Zydelig, Tablet, 150 mg (NDC 61958-1702-1) | — | — | Discontinuation in the manufacturing of the drug | — |
| To Be Discontinued | Zydelig, Tablet, 100 mg (NDC 61958-1701-1) | — | — | Discontinuation in the manufacturing of the drug | — |
These rows are manufacturer reports to the FDA for Idelalisib Tablet — they do not necessarily cover every manufacturer that makes this drug. A company appears here only if it told the FDA it has a supply problem, so other makers may still have stock. That’s the basis for the Where else can I get Idelalisib Tablet? options further down this page.
Why is Idelalisib Tablet in shortage?
Gilead Sciences has reported to the FDA that they are permanently stopping the manufacturing of Zydelig (idelalisib) tablets — both the 100 mg and the 150 mg strengths. This applies to both package sizes on file with the FDA (NDC 61958-1701-1 and NDC 61958-1702-1). That's why this product appears on the shortage list as "to be discontinued."
It's worth knowing that Gilead did not share a specific public reason explaining why they made this decision — just that manufacturing is being permanently stopped for both strengths. Also, this report reflects only what Gilead Sciences filed with the FDA, so it speaks only to their product and their supply.
Based on the manufacturer-reported reason(s) and notes on file with the FDA for Idelalisib Tablet, summarized in plain English by HelloPharmacist. A drug can be short for more than one reason, and the FDA updates these as manufacturers report changes.
What should I do if I take Idelalisib Tablet?
Idelalisib tablets (brand name Zydelig) are currently on the FDA shortage list, and I want to walk you through what that means for you.
Both strengths of this medicine are affected. Neither the 100 mg nor the 150 mg tablet has an available source right now, and the manufacturer on this record has reported that the product is being discontinued.
Because the reason listed is a discontinuation in manufacturing, this supply problem may be permanent rather than a short-term gap. Our records do not show another maker supplying the same medicine at this time, so the most important next step is a conversation with your care team.
Here is what I suggest, in order:
- Do not stop, skip, or change your dose on your own — keep taking it as prescribed while you sort out next steps.
- Ask your pharmacy to check with wholesalers and other manufacturers; local stock can differ from national reports.
- Contact your prescriber soon to discuss options, since this medicine is being discontinued and a clinician-chosen plan is the right path forward.
- The manufacturer's contact number is listed on this page for reference, though pharmacies usually handle those calls.
This is general information from national, manufacturer-reported data and may not match your pharmacy's actual stock. Your prescriber and pharmacist can guide the choice that fits you best.
- Don’t stop or change the medication on your own — talk to your prescriber first.
- If this is part of an ongoing or essential regimen (for example HIV treatment or prevention, seizure, heart, transplant, diabetes or mental-health medicines), do not skip or ration doses — contact your pharmacist or prescriber right away to arrange continued supply before you run out.
- Ask your pharmacy to check other manufacturers, strengths, package sizes, and nearby stores.
- Ask your prescriber whether a different strength, formulation, or the brand/generic version is appropriate.
Uses, dosing, side effects, prices, and the complete FDA label — written in plain English and pharmacist-reviewed.
Therapeutic equivalents & pricing 2 productsclick to expand
Orange Book–rated equivalents of the affected strengths, with the latest NADAC price (a federal retail-acquisition benchmark, not your copay) and an evidence-based availability label. Cheapest first.
| Product | Manufacturer | Package | NADAC $/unit | AB rating | Availability |
|---|---|---|---|---|---|
| Zydelig 150 mg | Gilead | 60 tablets | — | AB | FDA listed |
| Zydelig 100 mg | Gilead | 60 tablets | — | AB | FDA listed |
Equivalents share the same ingredient, strength, dosage form and route; an AB rating means the FDA considers them substitutable. NADAC is a national retail-pharmacy acquisition benchmark from CMS — not what you pay. Availability is inferred from recent pricing, not a stock check.
Other drugs in the same treatment class
These are different medicines — not other versions of Idelalisib Tablet — that fall in the same broad treatment class (antineoplastic systemic enzyme inhibitors) . They are not automatic substitutes: they can differ in how they work, dosing, effectiveness, side effects and what they’re approved to treat. Do not switch on your own. This list is for information only — ask your prescriber or pharmacist whether any of them is appropriate for you.
Identity & classification
Where does this data come from?
Other oncology shortages
Idelalisib Tablet shortage FAQs
Is Idelalisib Tablet in shortage?
Which products are affected?
When will Idelalisib Tablet be available again?
What should I do if I take Idelalisib Tablet?
Still have a question about the Idelalisib Tablet shortage?
Ask a pharmacist about this shortage →View Idelalisib Tablet on the FDA drug-shortage database →
Where does this data come from?
/drug/shortages) — drug, manufacturer & contact, NDC/product, status, availability, reason, therapeutic category and posting/update dates. Current / To Be Discontinued = active; Resolved is kept for history. The Supply-Risk rating is assessed per active ingredient and adds the FDA NDC Directory (still-marketed manufacturers by ingredient & form); same-medicine and equivalent products use First Databank classification + CMS NADAC pricing; Medicaid use + most-affected states come from CMS Medicaid State Drug Utilization Data. Reference only — confirm current status with the manufacturer or FDA before acting on it.